Abstract:Background: Influenza is a single-stranded RNA virus that is highly contagious and infects millions of people in the U.S. annually. Due to complications, approximately 959,000 people were hospitalized and another 79,400 people died during the 2017-2018 flu season. While the best methods of prevention continue to be vaccination and hygiene, antiviral treatments may help reduce symptoms for those who are infected. Until recently, the only antiviral drugs in use have been the neuraminidase inhibitors: oseltamivir, zanamivir, and peramivir. Objective: We reviewed novel drug targets that can be used in the treatment of influenza, particularly in the case of neuraminidase inhibitor-resistant strains that may emerge. Results: More recently, a drug with a new mechanism of action has been approved. Baloxavir marboxil inhibits the influenza cap-dependent endonuclease that is needed for the virus to initiate replication within the host cell. This endonuclease target is within the polymerase acid (PA) subunit of RNA polymerase. Since the RNA-dependent RNA polymerase consists of two other subunits, polymerase basic 1 and 2, RNA polymerase has several targets that prevent viral replication. Other targets still under investigation include viral kinases, endocytosis, and viral fusion. Conclusion: Due to the possibility of viral mutations and resistance, it is important to have antivirals with different mechanisms available, especially in the case of a new pandemic strain. Several novel antivirals are within various stages of development and may represent new classes of treatments that can reduce symptoms and complications in those patients who may be at higher risk.

Recent Progress of Novel Anti-Influenza Entry Inhibitors

Research Progress on Drug-Resistance of Influenza Virus to Neuraminidase Inhibitors

Recent advances in neuraminidase inhibitor development as anti-influenza drugs.

Emerging antiviral therapies and drugs for the treatment of influenza

Influenza Virus Cell Entry and Targeted Antiviral Development

Progress of Influenza Viruses and Inhibitors

New small-molecule drug design strategies for fighting resistant influenza A.

Current and novel antiviral strategies for influenza infection

The Development History, Structural Composition, and Functions of Influenza Viruses and the Progress of Influenza Virus Inhibitors in Clinics and Clinical Trials

Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle

Contemporary medicinal chemistry strategies for the discovery and optimization of influenza inhibitors targeting vRNP constituent proteins

Emerging Drug Design Strategies in Anti-Influenza Drug Discovery

Recent Advances in Application of Computer-Aided Drug Design in Anti-Influenza A Virus Drug Discovery

Development and Effects of Influenza Antiviral Drugs

Antiviral strategies against influenza virus: towards new therapeutic approaches

Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza

Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs"

Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit

Small Molecule Inhibitors of Influenza Virus Entry

Identification of entry inhibitors with 4-aminopiperidine scaffold targeting group 1 influenza A virus

Antiviral Potential of Natural Resources against Influenza Virus Infections